Results 1 to 10 of about 1,551 (70)
Biomarker Research, 2021 Eosinophilia represents a group of diseases with heterogeneous pathobiology and clinical phenotypes. Among the alterations found in primary Eosinophilia, gene fusions involving PDGFRα, PDGFRβ, FGFR1 or JAK2 represent the biomarkers of WHO-defined ...
Simone Romagnoli +11 more
doaj +1 more source
Blood Cancer Journal, 2021 Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality.
Paola Guglielmelli +15 more
doaj +1 more source
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
Frontiers in Oncology, 2021 The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its ...
Jerry L. Spivak, Alison R. Moliterno
doaj +1 more source
Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview
Frontiers in Oncology, 2021 The WHO-category Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) recognizes a unique group of clonal myeloid malignancies exhibiting overlapping features of myelodysplastic as well as myeloproliferative neoplasms.
Andrea Kuendgen +2 more
doaj +1 more source
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
Blood Cancer Journal, 2022 We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and 84 developed arterial and venous thrombosis ...
Alessandra Carobbio +10 more
doaj +1 more source
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms
Haematologica, 2011 Background Myeloproliferative neoplasms constitute a group of diverse chronic myeloid malignancies that share pathogenic features such as acquired mutations in the JAK2, TET2, CBL and MPL genes.
Damla Olcaydu +10 more
doaj +1 more source
Haematologica, 2012 We analyzed 636 patients with diverse myeloproliferative neoplasms or myelodysplastic/myeloproliferative neoplasms for mutations of the Casitas B-cell lymphoma gene (CBLmut) in exons 8 and 9 and performed correlations to other genetic alterations. CBLmut
Susanne Schnittger +12 more
doaj +1 more source
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
Revista Brasileira de Hematologia e Hemoterapia, 2011 Chronic myeloproliferative neoplasms arise from clonal proliferation of hematopoietic stem cells. According to the World Health Organization myeloproliferative neoplasms are classified as: chronic myelogenous leukemia, polycythemia vera, essential ...
Michelle Maccarini Barcelos +1 more
doaj +1 more source
Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms
Frontiers in HematologyThe myeloproliferative neoplasms (MPNs) – polycythemia vera, essential thrombocytosis, and primary myelofibrosis – are chronic blood cancers that originate from hematopoietic stem cells carrying driver mutations which activate cytokine signaling pathways
Joshua W. Bliss +4 more
doaj +1 more source
Haematologica, 2013 Most DNA methylation studies in classic Philadelphia-negative myeloproliferative neoplasms have been performed on a gene-by-gene basis. Therefore, a more comprehensive methylation profiling is needed to study the implications of this epigenetic marker in
Cristina Pérez +14 more
doaj +1 more source